智通财经APP讯，科笛-B(02487)发布公告，2025年8月28日，本公司与各配售代理订立《配售协议》，配售代理已同意担任配售代理，以本公司的代理身份按尽力基准促使承配人以每股 8.40港元的价格认购合共2890.4万股股份，相当于截至本公告日期本公司已发行股份(不包括库存股)的约9.05%。配售价每股8.40港元较2025年8月28日收市价每股9.55港元折让约12.04%。
扣除相关费用及开支后，预计配售所得款项净额约为2.4亿港元。本公司拟将配售所得款项净额作以下用途：约45%的配售所得款项净额将用于本公司在局部脂肪堆积管理、毛发疾病及护理、皮肤疾病及护理以及表皮麻醉管线的临床前研究开发和临床试验，以及用于相应生产设施及设备的布局; 约45%的配售所得款项净额将用于CU-40102(外用非那雄胺喷雾剂)及CU-10201(外用4%米诺环素泡沫剂)的市场推广活动、渠道拓展及品牌建设; 约10%的配售所得款项净额将用作营运资金及其他一般企业用途。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.